FIORINAL W/CODEINE
LOE ApproachingNDAORALCAPSULE
Approved
Oct 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FIORINAL W/CODEINE is a combination analgesic containing butalbital, aspirin, caffeine, and codeine phosphate in oral capsule form. It is indicated for tension headaches and migraines. The drug combines a barbiturate, NSAID, stimulant, and opioid to provide multi-modal pain relief.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure; expect transition planning and potential team restructuring as generics enter.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FIORINAL W/CODEINE offers limited direct career growth opportunities with zero linked job positions and an approaching loss of exclusivity. Roles tied to this asset focus on defensive strategy, generic transition management, and regulatory compliance rather than expansion.
Brand ManagerProduct Manager
Worked on FIORINAL W/CODEINE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.